Please find attached the BRSR for the financial year ended March 31, 2026

Date: 02/09/2026 National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Business Responsibility & Sustainability Report for the financial year 2025-26. Dear Sir/ Madam, Pursuant to Regulation 34(2)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed Business Responsibility and Sustainability Report (“BRSR”) of the company for the financial year 2025-26. The aforesaid BRSR is forming an integral part of the Annual Report for the financial year 2025-26 and can be accessed on the company’s website at www.morepen.com. This is for your information and records. Thanking you, Yours faithfully, For Morepen Laboratories Limited Vipul Kumar Srivastava Company Secretary Membership no. F 12148 Encl.: a/a. Morepen Laboratories Limited CIN NO. L24231 HP1984PLC006028 Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com BUILDING TODAY TRANSFORMING TOMORROW 66-67 ANNEXURE ‘D’ III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORTING Location Number of Plants Number of Offices Total National 4 2* 6 SECTION A: GENERAL DISCLOSURES International 0 0 0 I. Details of the listed entity *Corporate office at Gurugram and registered office at Baddi, Himachal Pradesh. 1 Corporate Identity Number (CIN) of the listed entity – L24231HP1984PLC006028 19. Markets served by the entity: 2 Name of the listed entity – Morepen Laboratories Limited a. Number of locations 3 Year of incorporation – 1984 Locations Number 4 Registered office address – Morepen Village, Nalagarh Road, Malkumajra, National (No. of States) 20+ Baddi, Solan, Himachal Pradesh, 173205 International (No. of Countries) 80+ 5 Corporate address – 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar- b. What is the contribution of exports as a percentage of the total turnover of the entity? III, Sector-20, Gurugram, Haryana-122016 The contribution of exports is 40% of the total turnover of the entity. 6 E-mail – investors@morepen.com c. A brief on types of customers 7 Telephone – +91-124-4892000 Morepen distributes its APIs globally across domestic, regulated, and semi-regulated markets, spanning over 80 countries. Its esteemed clientele includes leading global pharmaceutical companies such as Sandoz, Perrigo, 8 Website – www.morepen.com and Adamed, with a footprint extending across the USA, Germany, Poland, Japan, Korea, Russia, and Taiwan, as 9 Financial year for which reporting is being done – 01/04/2025 - 31/03/2026 well as Rest-of-World (ROW) markets like Bangladesh, Egypt, Algeria, and the Philippines. Additionally, the company supplies medical devices and formulations directly to the retail segment. 10 Name of the Stock Exchange(s) where shares are listed – National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE") Customer Type Description Key Needs 11 Paid-up Capital – `109,58,41,398 Retail Customers Individual end-users buying Quality, affordability, ease OTC and wellness products of use, accessibility 12 Name and contact details (telephone, email address) – Mr. Sanjay Suri of the person who may be contacted in case of any Whole-Time Director Pharmacies & Retailers Physical stores selling the company's Reliable supply, competitive queries on the BRSR report sanjay.suri@morepen.com products to consumers pricing, variety +91-1795-266401-03 Hospitals & Clinics Healthcare institutions and professionals Quality, regulatory 13 Reporting boundary - Are the disclosures under this – Standalone basis compliance, technical support report made on a standalone basis (i.e. only for the Distributors & Wholesalers Bulk buyers supplying to retailers Consistent supply, favourable entity) or on a consolidated basis (i.e. for the entity and institutions margins, logistics and all the entities which form a part of its consolidated financial statements, taken together). E-commerce Customers Online buyers via the company's site Convenience, quick delivery, or e-commerce platforms authenticity 14 Name of assessment or assurance provider – Not mandated for FY 25/26 Corporate & Institutional Organizations buying for employees Custom solutions, bulk pricing, 15 Type of assessment or assurance obtained – Not mandated for FY 25/26 or bulk needs after-sales II. Products/services Business to Business buyers Supply of API to formulation Quality, Regulatory and supply 16. Details of business activities (accounting for 90% of the turnover): (for API) manufactures and traders assurance S. Description of Main Activity Description of Business Activity % of Turnover of the entity IV. Employees No. 20. Details as at the end of Financial Year: a. Employees and workers (including differently abled) : 1. API Business Products like Loratadine, Montelukast, 56.33% Atorvastatin etc S. Particulars Total (A) Male Female 2 Medical Devices Business BP Monitors, Glucometers etc 35.60% No. No. (B) %(B/A) No.(C) %(C/A) EMPLOYEES 17. Products/Services sold by the entity (accounting for 90% of the entity's Turnover): 1. Permanent (D) 1314 1188 90.41% 126 9.59% S. Product/Service NIC/HSN/SAC % of total Turnover 2. Other than Permanent (E) 0 0 0 0 0 No. Code contributed 3. Total Employees (D+E) 1314 1188 90.41% 126 9.59% 1. Manufacture of pharmaceuticals, medicinal and chemical 210099 56.33% product (Active Pharmaceutical Ingredients) WORKERS 2. Manufacture of other medical and dental instruments 325005 35.60% 4. Permanent (F) 605 564 93.22% 41 6.78% n.e.c. (Diagnostics) 5. Other than Permanent (G) 1150 967 84.09% 183 15.91% 6. Total Workers (F+G) 1755 1531 87.24% 224 12.76% BUILDING TODAY TRANSFORMING TOMORROW 68-69 b. Differently abled Employees and workers: VI. CSR Details S. Particulars Total (A) Male Female 24. (I) Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes No. No. (B) %(B/A) No.(C) %(C/A) (ii) Turnover (in `) 16,76,66,92,000 (Note: This is the turnover from operations) DIFFERENTLY ABLED EMPLOYEES (iii) Net worth (in `) 12,45,41,00,000 1. Permanent(D) 0 0 0 0 0 VII. Transparency and Disclosures Compliances 2. Other than Permanent(E) 0 0 0 0 0 25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible 3. Total Differently abled employees (D+E) 0 0 0 0 0 Business Conduct: DIFFERENTLY ABLED WORKERS 2025-26 2024-25 4. Permanent(F) 0 0 0 0 0 Stakeholder Grivance (If yes then- Number of Number of Remarks Number of Number of Remarks 5. Other than Permanent(G) 1 1 100% 0 0 Group Redressal provide web-link complaints complaints complaints complaints from whom Mech- for grievance filed during pending filed during pending 6. Total Differently abled workers (F+G) 1 1 100% 0 0 complaint anism redress policy) the year resolution the year resolution 21. Participation/Inclusion/Representation of women: is received in Place at close at close of (Yes/No) of the year the year Total (A) No. and percentage of Females Communities Yes 0 0 – 0 0 – No(B) %(B/A) Investors Yes 0 0 – 0 0 – Board of Directors (BoDs) 6 1 16.67% (other than Key Management Personnel 4* 0 0% shareholders) *Two of the KMPs are part of the BODs Shareholders Yes 2 0 – 0 0 – Yes, the company 22. Turnover rate for permanent employees and workers (in%) Employees Yes 10 0 – 13 0 Refer to have a unied and workers Qn13 of FY 2025-26 FY 2024-25 FY 2023-24 Grievance Principle Redressal Policy 3 of BRSR Male Female Total Male Female Total Male Female Total which can be report of Permanent Emp [Showing first 8,000 characters — download PDF for full document]